why is the health sector full of imperfections, despite huge investments and increasing literacy rates? Satya Brahma

Satya Brahma, Chairman & Editor-In-Chief of Pharmaleaders opened up the debate with a scathing attack on the dual standard of the Government to encourage domestic Pharma companies & minimize the presence of the Multi-National Companies. Satya Said “ In an era of Globalization, free trade & inter commercial relations which has brought india to the world map, the attempt by the Government of India of not taking the consensus on factors such as FDI, Reforms, Free Medicines policy & Pricing are unfortunate & deplorable. Pharmaleaders, Asia’s Biggest voice in healthcare Communications & Media debated on “Brand India”, Beyond Generics - Leading with Resilience - Coming Back from Challenge and Heading towards Super-power Status is going to be the business mantra of today’s debate. Widely perceived by Industry’s Opinion Leaders & Analysts as the Centre-Point of debating complex & serious issues, pharmaleaders platform witnessed more than 20 top Industry Leaders deliberating on complex issues of this sensitive Industry.  

Questioning the intent of the Government, Satya Brahma stated “why is the health sector full of imperfections, despite huge investments and increasing literacy rates?. There are a number of factors responsible for it — lack of public financing, huge information asymmetry between consumers and the providers, lack of coherence in policy formulation between the Centre and States on the subject of healthcare and absence of proper regulatory oversight. Healthcare infrastructure, insurance coverage, disease prevalence, and patient population are the key fundamentals driving the healthcare industry into the future the current density demand indicated shortfall of hospital beds, doctors and nurses. The estimated requirement by 2025 is 1.75 million beds, 0.7 million doctors and 1.6 million nurse. Achieving this target will require a total investment of US$ 77.9 billion. Pharma market is expected to grow to US$ 54 billion. In 2010, it was cardiovascular and diabetes which are the fastest growing and the two diseases will continue to register 18 per cent and 20 per cent growth in terms of hospital admissions and therapies”.

India’s Most Admired Cardiac Surgeon Dr Hariawala Raises Protest Over Artificial heart’s mockery

India’s Most Admired  Cardiac Surgeon Dr Hariawala Raises Protest Over Artificial heart’s mockery

Healthcare Economist & Eminent Cardiac Surgeon lashes out at marketing Gimmicks played over Artificial Heart by His Contemporary Peers.

Monday, 24^th September 2012, Mumbai, Maharashtra : India’s much acclaimed & World renowned Cardiac Surgeon & Healthcare Economist Dr Mukesh Hariawala  who recently shot to fame with his stunning presentation on Is India prepared for a Artificial Heart Surgery at his much anticipated Keynote Address that virtually stunned the audience who had gathered in large numbers from the pharmaceutical Industry, Medical Professionals at Pharmaleaders 5^th Annual Pharmaceutical Leadership Summit & Business Leadership Awards 2012 in a suburban hotel in Mumbai on 21^st September 2012 organised by Pharmaleaders in association with Pharmexcil, Ministry of Commerce to debate on the Healthcare Reforms in India. The Summit felicitated top 33 performers in healthcare industry.

Satya Brahma, Chairman & Editor-In-Chief of Pharmaleaders opened up the debate with a scathing attack on the dual standard of the Government to encourage domestic Pharma companies & minimize the presence of the Multi-National Companies. Satya Said “ In an era of Globalization, free trade & inter commercial relations which has brought india to the world map, the attempt by the Government of India of not taking the consensus on factors such as FDI, Reforms, Free Medicines policy & Pricing are unfortunate & deplorable. Pharmaleaders, Asia’s Biggest voice in healthcare Communications & Media debated on “Brand India”, Beyond Generics - Leading with Resilience - Coming Back from Challenge and Heading towards Super-power Status is going to be the business mantra of today’s debate. Widely perceived by Industry’s Opinion Leaders & Analysts as the Centre-Point of debating complex & serious issues, pharmaleaders platform witnessed more than 20 top Industry Leaders deliberating on complex issues of this sensitive Industry.  

Questioning the intent of the Government, Satya Brahma stated “why is the health sector full of imperfections, despite huge investments and increasing literacy rates?. There are a number of factors responsible for it — lack of public financing, huge information asymmetry between consumers and the providers, lack of coherence in policy formulation between the Centre and States on the subject of healthcare and absence of proper regulatory oversight. Healthcare infrastructure, insurance coverage, disease prevalence, and patient population are the key fundamentals driving the healthcare industry into the future the current density demand indicated shortfall of hospital beds, doctors and nurses. The estimated requirement by 2025 is 1.75 million beds, 0.7 million doctors and 1.6 million nurse. Achieving this target will require a total investment of US$ 77.9 billion. Pharma market is expected to grow to US$ 54 billion. In 2010, it was cardiovascular and diabetes which are the fastest growing and the two diseases will continue to register 18 per cent and 20 per cent growth in terms of hospital admissions and therapies”.

Dr Mukesh Hariawala, who was felicitated the coveted India’s Most Admired Surgeon of India by Maharashtra Governor K.Shankaranarayanan, said that india is on the move & unveiled triple heart therapy in his keynote Address. To quote Dr Mukesh Hariawala “ Artificial  Heart is not the scientific term but it should be VAD ( mechanical ventricular assist device ) as in this operation the native heart is not removed from the chest and replaced. Also Angiogenesis , Stem cells must be correctly explained that it is not a magic wand but will play a synergistic role with conventional and proven bypass surgery. Finally, unlike other Indian cardiac surgeons who want to indulge in sensationalism journalism , I would like my image as a credible surgeon scientist whose mission is to provide accurate meaningful educational information to the Indian readership , doctors and patients. Dr Hariawala wanted to maintain peer respect of fellow doctors and said he had no interest in becoming overnight medical hero in India. Hariawala stated that he wanted to give back  his expertise to motherland India which will help poor patients with heart diseases. He countered Dr Ramakant Panda’s view that “A tiny mechanized device weighing 400 grams may soon give a new lease of life to more than 4 million people in the country who die of heart failure every year. A Mumbai hospital has brought in the technology to implant an artificial heart that takes over the functioning of the original heart and promises to double the patient's life-expectancy. Artificial heart now in India, price Rs 1 crore” as reported in Media”. Interestingly Dr panda was the previous recipient of the Award Title as India’s Most Admired Surgeon at the same platform in its 4^th Annual Edition.

Dr Hariawala unveiled 3 new revolutionary cardiac technologies , Dr Hariawala's pioneering Triple Heart Therapy ( Angiogenesis + Stem Cells + Laser ) best done in a " Hybrid Operation Suite " , VAD ( Ventricular Assist Device ) and Non Invasive Shockwave Therapy in India. The FDA or CE mark approved VAD's, which will be offered to patients as an alternative to Heart Transplantation, has a cumulative worldwide Implantations record which has crossed 10,000. The " Optimal VAD for India " would be one that has a good track record of reliability, minimal complications and competitive shelf price. Elaborating on the long life lithium ion battery operated VAD's which plays the role of a Mechanical Artificial Heart, Dr Hariawala told ANI in an exclusive interview, that VAD is only for patients who are in advanced stage heart failure and who do not qualify as patients for routine angioplasty, stent or bypass surgery. VAD patients following implantation will be able to ambulate and begin enjoying an improved quality of life with certain restrictions, he said.

Storz Medical's unique " MODULITH - SLC Shock Wave " Non - Invasive system has an excellent record with CE certification that employs the principles of " Therapeutic Angiogenesis ". This easy to deliver technology is ultrasound image guided. The controlled targeted level of shock wave energy stimulates the release of cellular growth factors like VEGF helping in formation of micro blood vessels from pre existing ones. This resultant effect is provision of a large pool of oxygen rich collateral vessel network which supports circulation to the failing heart, thus giving early relief of angina related symptoms. The advantage of this technology is negligible incidences of procedural complications, and is best suited for most Indian patients who have diabetes, diffused extensive non bypass-able coronary artery disease and who are in need of repeat bypass surgery but are high risk subjects . The well established EECP ( External Enhanced Counter Pulsation ) technology works on the same principle using inferior extremity cuffs. Boston, US based Dr Mukesh Hariawala is also a Visiting Honorary Cardiac Surgeon at Mumbai's Jaslok Hospital. In addition to performing open heart surgery on many worldwide celebrities, Dr Hariawala along with Dr John Wright had performed the first Bypass operation in London on Prime Minister Dr Manmohan Singh in 1990

Aanjaneya Lifecare Bagged Coveted BSE Award for Best Return to Investors, Padmashree Dr Mukesh Batra is Business Leader of the Year, Dr Mukesh Hariawala as India’s Most Admired Surgeon & Thirty Three top Asia Pharmaleaders Felicitated

Aanjaneya Lifecare Bagged Coveted BSE Award for Best Return to Investors, Padmashree Dr Mukesh Batra is Business Leader of the Year, Dr Mukesh Hariawala as India’s Most Admired Surgeon & Thirty Three top Asia Pharmaleaders Felicitated

Maharashtra Governor K. Shankanarayanan urges Industry Leaders to make Maharashtra as Manufacturing Hub for Pharmaceutical Productions, Confers top Awards to Veterans of the Healthcare Industry

Pharmaleaders’s 5th Annual Pharmaceutical Leadership Summit & Business Leadership Awards 2012 held at Hotel Hilton Mumbai International Airport, Mumbai, India Brand India : Beyond Generics, Growth, Challenges & Developments in Mumbai on Friday, the 21st September 2012 at Hotel Hilton Mumbai International Airport witnessed more than 250 Business Tycoons, Owners of Pharma Companies, Government Officials, Doctors, Overseas Companies, Policy Makers & Bureaucrats. In a historic address Satya Brahma, Chairman & Editor-In-Chief of Pharmaleaders Magazine addressing in his opening address lambasted the Government of lack of political will to bring a consensus on the issue of “Free Medicines” as the Central Government has put in place a $5.4 billion policy to provide free medicine to its people, a decision that could change the lives of hundreds of millions. From city hospitals to tiny rural clinics, India's public doctors will soon be able to prescribe free generic drugs to all comers, vastly expanding access to medicine in a country where public spending on health was just $4.50 per person last year. “While welcoming the decision of such move, there are apprehensions that the decision could in fact divide the opinions of the MNC’s & Domestic Pharma Majors as Medical Doctors who have been practicing with their respective practices of established pharmaceutical Companies with the research molecules & have spent years to ensure the efficacy of drugs & undergoing Clinical Trials with the approved laboratories, It indeed will be disastrous considering the process & mechanism of its implementations & Patient Safety will be a biggest Challenge”..

Among those who addresses at the prestigious Summit of Pharm leaders included the veterans & Top Doctors on topics that mattered most such as Challenges and Opportunities for Indian Pharma Industry to become Pharma Superpower in 2020 by Dr Mahesh Burande, Hon Director,Institute of Pharmaceutical Education and Research (IPER). Branded Formulations VS Branded Generics, 2012 Pharmaceutical Diversification Trends by Kewal Handa, Ex Managing Director, Pfizer Ltd. & Wyeth Ltd, Making of Dr Batras Brand, Indian Experience VS Global Challenges by Dr Mukesh Batra.Founder Chairman, Dr Batra’s Positive Clinic, Are We Ready For A “Mechanical Artificial Heart For Indian Patients by Dr Mukesh Hariawala, Cardiac Surgeon & Healthcare Economist, Harvard Medical School Affiliated Hospitals, Boston, USA. Regulatory Challenges of Indian Pharmaceutical companies. A CEO’s Perspective by Dr. Shenaz Khaleeli ,Co- Founder & Technical Director, PharmaLeaf India Pvt Ltd, Delivering value in the Supply Chain by Sue Arden, VP Life Sciences & Healthcare. DP DHL, Singapore, Neutraceutical & OTC Sector: The European Market Challenge by François Licoppe, CEO,Eubage Laboratory, Belgium, Indian Pharma Industry : Challenges & Key Issues in partnership, Alliances & Co-Marketing by Shivkumar Kunchithapatham, Managing Director, Eisai Pharmaceuticals India Private Limited, Innovative Trends in Facial Aesthetics – Indian Challenges with Global Experiments by Dr. Shuba Dharmana Cosmetic Dermatologist, Laser Specialist, Hair Transplant Surgeon, CEO Dr.Shuba Skin & Laser Clinic.

The Highlight of the Summit was that of much awaited lecture by Indo-Americam Cardiac Surgeon & Healthcare Economist Dr Mukesh Hariawala. Dr Hariawala stunned the audience by showing an Artificial Heart & a video clip where a working woman was seen exercising without having a Natural Heart as the Artificial Heart was used. He also unveiled the triple heart therapy & 100 Billion $ Medical Tourism Opportunities for India.

In his Chief Guest Address, Maharashtra Governor K. Shankaranaranan said that “Pharmaleaders Magazine has also presented our healthcare industry to the global platforms being the largest research based & technologically innovative hub of Healthcare Companies. Pharmaleaders Magazine since last one decade has been organizing world-class “Pharmaceutical Leadership Summit & Excellence Awards” year after year to create a platform for knowledge sharing & dissemination of innovative ideas from the stalwarts of the Industry”. Maharashtra contributes substantially to the pharmaceutical sector of India. A large amount of the drugs and pharmaceuticals produced in the country are manufactured here. It has the maximum number of active pharmaceutical ingredients (APIs) units. Hence the pharma industry of the state has played a crucial role in making Indian pharmaceutical industry a global leader in generic medicines. Maharashtra has been a hub for the pharma industry, both in terms of manufacturing as well as supply of materials. It has been a rich breeding ground for innovation, a source of abundant skilled and diverse manpower which could effectively support the pharma sector in the past”.

The Award Winners were declared ending 66 days of voting by a Nationwide Nominations & Juries Decision.

Those who were awarded are.

1.Business Leader of the Year 2012

Dr. Mukesh Batra

Founder Chairman,

Dr Batra's Positive Health Clinic Pvt. Ltd

2.Business Woman of the Year 2012

Ms. Shenaz Khaleeli,Founder and CEO, PharmaLeaf India.

3.Dynamic Entrepreneur of the Year 2012

Dr. Rajaram Samant, MD, Akumentis Healthcare Ltd

4.Pharma OTC Company of the Year 2012

Ranbaxy Ltd

5.India’s Most Admired Nutrition & Neutraceutical Company of the Year 2012

Elder Pharmaceuticals Ltd

6.Pharma Company of the Year 2012

Fourrts (India) Laboratories Pvt. Ltd.

7.Pharma CSR Organisation of the Year 2012

Microlabs Ltd

8.Pharma Professional Of the Decade 2012 ( Four Winners) Four Trohphie

1.Mr. Ashok Jain, Executive Director, Microlabs Ltd.

2.Dr. Hasit Joshipura, Vice President, South Asia & Managing Director – India, GlaxoSmithKline Pharmaceuticals Ltd

3.Mr Arun Sawhney, MD, Ranbaxy Ltd.

4.Dr Alok Mishra, Managing Director, Advaita Pharma Pvt Ltd.

9.Lifetime Achievement Award 2012

1.Mr Deepak Pahwa, Chairman, Pahwa Enterprises.

2.Mr N.R.Munjal, Chairman, Ind-Swift Ltd.

3.Mr Kashi Vishwanath, Chairman, Aanjaneya Lifecare Ltd.

4.Dr.Appaji PV, Director General, Pharmexcil India ( Pharmacy Profession)

10.Brand of the Year 2012

Revital & Volini

11.Innovative R & D Company of the Year 2012

Microlabs Ltd.

12.India's Most Admired Surgeon Of the Year 2012.

Dr Mukesh Hariawala, Cardiac Surgeon & Healthcare Economist.

13.India's Fastest Growing Pharmacy Retail chain 2012

Trust Chemists & Druggists Ltd.

14.India’s Most Promising Entrant into The Big League

Ind-Swift Ltd.

15.Emerging Company of the Year 2012

Akumentis Healthcare Ltd.

16.India’s Most Admired Company in Bulk Drugs 2012

Granules India Ltd .

17.India’s Most Admired Company in Exports 2012

Granules India Ltd

18.India’s Most Admired Promising Hospital Chain 2012.

Global Hospitals Group

19.Upcoming Biotech Pharma Company of The Year 2012.

Adroit Biomed Ltd.

20.BSE Award for the Best Return to Investors

Aanjaneya Lifecare Ltd.

21.India’s Most Promising Cosmetologist & Non-Surgical Aesthetic Medicine Award

Dr Rashmi Shetty. CEO, Ra Skin and Aesthetics.

22.Woman Entrepreneur of The year ( Joint Winners)

1.Ms. Shalini Kumar Saxena, Elder Instruments

2.Dr Shuba Dharmana, CEO, Dr Shuba’s Clinic.

23.India’s Most Promising Outsourcing Pharma Company in CRAMS.

Akums Drugs & Pharmaceuticals Limited.

24.Young Pharma Entrepreneur of The Year 2012

Mr J.P.N. Singh, Director, Galpha Laboratories Ltd.

25.Global Indian of The Year Male 2012

Dr B.R.Shetty, Chairman, NMC Healthcare.

26.Global Indian Woman of The Year 2012

Dr Kiran Mazumdar Shaw, CMD, Biocon Ltd.

27.India’s Most Promising Pharmaceutical Education & Consulting Institution

The Institute of Pharmaceutical Education and Research (IPER).

28.Most Promising HR Consulting Firm

Kegan Executive Search

29.Transformational Pharma Leader of the Deacde

Kewal Handa, Managing Director, Pfizer India Ltd.

30.First Generation Woman Entrepreneur of the Year 2012.

Ms Nidhi Saxena, CEO & MD, Karmic Lifesciences

31.India’s Most Preferred Pharmaceutical Group in CRAMS Management.

Medreich Ltd

32.Research Scientist of The Decade

Dr Himadri Sen, Board of Director, Strategy and Scientific Affairs Unimark Remedies & Hon. Patron, I.P.E.R.

33.NGO of the Year 2012

123 Global Organizations

About Pharmaleaders Magazine

Pharmaleaders Magazine, India’s first opinion based & research driven bi-monthly magazine has finished two memorable glorious years of its relentless reporting in Pharma Journalism in a unbiased, fearless & independent way. Over the last two year, The Magazine has covered some of the biggest voices in healthcare Industry. Available both in digital & printed format, Pharmaleaders has emerged out as a leading title in voicing the opinion of the healthcare industry to the statutory Authorities like Ministry of Health & Family Affairs, Dept of Chemicals & Fertilizers, DCGA, FDA & many other institutions to present the pressing demands of the healthcare industry. Pharmaleaders Magazine has also presented our healthcare industry to the global platforms being the largest research based & technologically innovative hub of Healthcare Companies. Pharmaleaders Magazine since last one decade has been organizing world-class “Pharmaceutical Leadership Summit & Excellence Awards” year after year to create a platform for knowledge sharing & dissemination of innovative ideas from the stalwarts of the Industry.

BSE Award For “Best Return To Investors” at 5th Annual Pharmaceutical Leadership Awards 2012 Intensifies

 BSE Award For “Best Return To Investors” at 5^th Annual Pharmaceutical Leadership Awards 2012 Intensifies

Aanjaneya Lifecare, Divis Laboratories, TTK Healthcare,Ajanta Pharma are in the race for the prestigious title as India votes to choose the company who has maximized their Returns on Investments.

Mumbai, September 13, 2012: Pharrmaleaders, Asia’s biggest title in healthcare communications is gearing up to choose the top Pharmaceutical & Biotech Companies for their dramatic & significant accomplishments in their respective field at the 5^th Annual Pharmaceutical Leadership Awards 2012 in as many as 33 categories, the biggest & coveted title that India is anxiously looking at is the Category that has made investors & stakeholder happy in the stock market. Organized in association with BSE, Pharmexcil, IBEF & Ministry of Industry & Commerce, Government of India, the coveted  & prestigious title BSE  Award for the Best Return to Investors 2012 will be presented by Shri K. Shankaranarayan, His Excellency, Governor of Maharashtra on Friday 21^st September at Hotel Hilton Mumbai International Airport amidst the presence of the veterans & who’s who’s of the Asia’s top Healthcare Leaders, Pharma Academia, Ministers, Policy Makers, Social Entrepreneurs & Medical Practioners. More than top 200 professionals of the Industry are expected to attend the much awaited Leadership Event with the representation of Overseas Companies.

Speaking on the Award Nomination, Kersi Tavadia, CIO at Bombay Stock Exchange Limited said “Pharmaleaders has institutionalized Pharmaceutical Leadership Awards since 1999 to honour & recognize the successful companies & individuals who have made their mark & contributed vigorously to the growth of Indian Economy & foreign exchange. Although there are many successful Pharmaceutical Companies listed in BSE are doing well, however, the attempt by the juries to nominate the mid-sized companies such as Aanjaneya Lifecare, Divis Laboratories, TTK Healthcare,Ajanta Pharma are indeed judicious choices as all four companies are doing exceedingly well in the Healthcare Index. The Public, Investors & Companies who are choosing the Winner will truly be a fitting recognition”.  Satya Brahma, Chairman of the Juries & Editor-In-Chief of Pharmaleaders said “ This category has attracted tremendous attention in the stock market, Pharma Companies & in the general public as corporate ethics, Corporate Sustainability Model are the norms of the day & with so much of scrutiny by the regulators, BSE Award for the Best Return to the Investors will be a tight contest”.               

Kiran Kabtta Somvanshi  of ET said “ Of late there are many Midcaps in Healthcare doing exceedingly well. Consider this, the stocks of most leading pharma companies have hit a new high or a 52-week high since August. Stocks of companies like Cipla, Sun Pharma, Lupin, Wockhardt, Strides Arcolabs, Divi's Labs, Ipca Labs, Indoco Remedies Alembic Pharma and Shasun Pharma have hit a new high on the bourses. Likewise, stocks of Ranbaxy Labs, Glenmark Pharma, Dishman Pharma, Cadila Healthcare, Unichem Labs and Venus Remedies have hit a 52-week high. With macro economic conditions being difficult and most sectors not doing well, the market is chasing all growth-oriented companies in the defensive sectors of FMCG and now Pharma stocks, defensive sector, valuations, FMCGarma.Given the limited opportunity in the market, the Street has now turned to pharma stocks to capture growth and value. Most pharma companies with decent growth performance has witnessed a rally in its stock. 32% of the total 148 listed pharma stocks have flared up to new or 52-week highs in the last one month.The Indian pharma market is growing at 16-18%. Most Indian companies earn substantial revenues from outside by selling low-cost generic drugs in regulated markets. The industry is growing at an average rate of 20-22%. Many Indian companies like Sun Pharma, Dr Reddy's Labs and Glenmark are among the fastest growing generic companies in the world. With the market now chasing the drug company stocks, the valuations of these companies is likely to become expensive. The ET Pharma Index is trading at a price to earnings multiple of 33 very close to the 34.6 P/E of ET FMCG Index.

Dr Kannan Vishwanath led Aanjaneya Lifecare which specializes in niche segments has a strong presence in API and formulation business and has bulk drug manufacturing facility at Mahad and a finished dosage forms unit near Pune. It is one of the largest contract manufacturers of codeine-based cough syrups in India and exclusively makes Codorex brand of Zydus Cadilla and Codilite tablets among others. It recently raised around Rs 117 crore through an initial public offering (IPO). It acquired recentlyApex Drugs and Intermediates (ADI), a Hyderabad-based integrated active pharmaceutical ingredient (API) and intermediate company, for Rs.250 crore, including debt of Rs.185 crore and equity dilution of Rs.65 crore.

Divi’s Laboratories has earned a consolidated total income of Rs.722 crores for the 4th Quarter of the year 2011-12 as against a total income of Rs.480 crores during the corresponding quarter last year, reflecting a growth of 50%. Established in the year 1990, with Research & Development as its prime fundamental, Divis  Laboratories focussed on developing new processes for the production of Active Pharma Ingredients (APIs) & Intermediates. The company in a matter of short time expanded its breadth of operations to provide complete turnkey solutions to the domestic Indian pharmaceutical industry.

Purushottam B. Agrawal Led Ajanta Pharma is a specialty pharmaceutical company engaged in the development, manufacture and commercialization of pharmaceutical products. We employ over 3,500 people worldwide and our products are sold in over 30 countries. Ajanta operates with 5 state-of-the art manufacturing facilities that produce high quality pharmaceutical products. We focus on commercializing unique generic products and pioneering synergistic combination products in the therapeutic areas of anti- malarial, cardiology, dermatology, gastroenterology, musculoskeletal, ophthalmology and respiratory is also doing quite well.

Chennai based TTK Healthcare manufactures calcium supplements, haematinics, cervical dilators, thrombolytic agents, rejuvenators, multimineral supplements, liver correctives and pain management products.Besides being the first Pharmaceutical Company in India to be awarded the ISO certification by BIS, TTK Healthcare was also the first to launch technology-driven life-saving products like Urokinase and Dopamine. The Company has also developed medicines like Lactare based on Ayurveda - the ancient traditional system of medicine.

About 5^th Annual Pharmaceutical Leadership Awards 2012.

Pharmaceutical Business Leadership Award Nominations 2012 has been carefully selected in 33 categories with several new entrants making it to the top category & big league as a result of their rising market presence. While the traditional Award Nominations have remained, some more categories have been created by the juries to give justice to the young companies & Leaders, further a great emphasis has been given to some of the unsung heroes & their innovative growth Stories. Pharmaleaders has taken every possible steps to keep the award nominations credible & newsworthy. While more than 500 top houses have been honored with their names featuring in Annual Reports & international platforms, Pharmaceutical Leadership Business Leadership Awards are widely perceived to be most credible & independent & free from political interference. The three tier judging mechanism allows each nominee to undergo a public scrutiny first by the SMS, Email & than the eminent Juries will decide the fate of achievers tonight. In a significant development, Pharmaleaders has introduced a unique mechanism of creating mote than 5 Lakh sample size consisting of Companies, Pharmacy Education, Trade, Investors & Doctors.

Originally launched in 1999 as the Pharma Business & Technology Excellence Awards, The Excellence Awards were first produced for the first time in India by the PHARMA BUSINESS & TECHNOLOGY MAGAZINE as a means of honoring innovation in pharmaceutical marketing, corporate governance, Research and development & Lifetime Achievements category. Pharma Excellence Awards were produced by PHARMA BUSINESS & TECHNOLOGY MAGAZINE Awards in India and expanded to recognize global corporate citizenship and individual achievements. Over the last one decade, Pharmaceutical business leadership awards 2012 has been re-evaluated and recast to focus more on business-scientific accomplishments in the biotech industry with a significant thrust in academic pharmaceutical research. The set of awards have been presented since last one decade at a sold-out gala to over 500 industry executives and leading academic scientists from around the world. Each Award or Nomination are being screened by the Board Members of Pharma Leaders Group consisting of 12 Member Team & than further approved by Network 7 Media Group Editorial Members from Pharmanewsprwire, Indian Affairs Juries consisting of eminent members of the Healthcare Community. After through screening, the names of four Nominees emerge out & are thrown out to public by E-mail Voting, Than SMS Voting followed by the final verdict of the Jury Members. The Awards demonstrate how companies can, through their core business activities, help achieve excellence in innovations. The 2012 Award Nominations has been given explicitly to companies delivering inclusive business models which are sustainable, commercially-viable business initiatives that expand access for low-income people to goods and services, or improve their livelihoods by engagement in value chains as direct employees, suppliers or distributors, while also generating sales and profit growth. By bringing together examples of innovative, effective business practices, 5th Annual Pharmaceutical Leadership Awards will also provide leading businesses and entrepreneurs with a valuable platform for networking and sharing experiences, and promote best practices. This will encourage other businesses and governments to replicate and scale initiatives. In 2011, the Awards received an unprecedented 172 nominations, representing a variety of business and commercial endeavors undertaken by business associations, non-governmental organizations and individual companies from more than 9 countries with a sample size of 5 Lakh 56 thousand & 674 voters spread across 21  states & 4 industry verticals via online, sms & physical interviews . “Past Award winners have shown how companies can help boost sustainable growth and development & they can be a tremendous source of innovative and sustainable solutions, which help transform people’s lives for the better." These Awards will highlight the critical role of the private sector in stimulating sustainable economic growth and development. A detailed Analysis of career graph/History or notable achievement is looked at to get the final four names. Such as

•             Financial management, 

•             Decision making roles and business impact. •Business ethics.

•             Managing rapid growth.

•             Innovation.

•             Adapting to change.

•             Strategic partnerships.

•             Leadership roles.

•             Marketing strategies.

•             Corporate philanthropy to society.

The Award for the Best Return to Investors will be presented once the results for the Nomination process will end & the final vote count on 21^st September . The Winner will be presented an Award Trophy & a certificate of Excellence.

Maharashtra Governor Kateekal Sankaranarayanan is the chief at Pharmaleaders’s 5th Annual Pharmaceutical Leadership Annual Summit & Business Leadership Awards 2012

Maharashtra Governor  Kateekal Sankaranarayanan is the chief at Pharmaleaders’s 5^th Annual Pharmaceutical Leadership Annual Summit & Business Leadership  Awards 2012

His Excellency Kateekal Sankaranarayanan will give away Awards to the Shining Stars of Indian Healthcare Industry & Address to the Industry Gatherings.

Mumbai, Maharashtra,12^th Sept 2012 : Pharmaleaders’s much awaited Annual Leadership Event 5^th Annual Pharmaceutical Leadership Summit & Business Leadership Awards 2012 ( www.asiapharmaleaders.com ) will be graced & inaugurated by Maharashtra Governor Kateekal Sankaranarayanan to be held in Mumbai on Friday, the 21^st September 2012  at Hotel Hilton Mumbai International Airport, Mumbai India. Organised by Pharmaleaders ( www.pharmaleaders.co.in ) in association with Pharmexcil, India Brand Equity Foundation (IBEF), Breakfast News TV ( www.breakfastnews.tv ) with the support of Ministry of Commerce & Industries, Government of India & several other leading trade bodies, Pharma Industry organizations. The widely awaited much acclaimed  event of Asia’s Biggest Leadership Event entering in its 5^th glorious years, Pharmaceutical Leadership Summit & Business Leadership Awards 2012 under the theme “Brand India, Beyond Generics, Leading with Resilience: Coming Back from Challenge and Heading Towards Super-power Status” will be attended by more than top 200 owners of the  Indian Pharmaceutical Industry, CEO’s & veteran think-tanks including leading medical practitioners, Pharma Academia, consultants, policy makers besides attendance from overseas companies from middle east, Europe & Gulf.

Speaking on the announcement of His Excellency, Maharashtra Governor  Kateekal Sankaranarayanan’s participation as Chief Guest of the Pharmaceutical Leadership Summit 2012, Satya Brahma, Editor-In-Chief of Pharmaleaders & Chairman of the organizing Committee of the 5^th Annual Pharmaceutical Leadership Summit said “ The consent of the Maharashtra Governor  K .Sankaranarayanan’s presence as Chief Guest at the much awaited Asia’s largest get together plattform is indeed  big news considering the magnitude of the Event & no other dignitaries could have added such grace 7 prestige to the event other than His Excellency. We are excited & thrilled as the highest constitutional post of the Maharashtra Government will be the chief Guest to give away the awards & address to the who’s & Who’s of the Indian Healthcare Industry. “Governor Shankaranarayan has glorious track record as an able administrator & hails from Kerala & held several key posts including the Finance Minister in Kerla in the past & is a popular mass leader”, said Satya.

5^th Annual Pharmaceutical Leadership Summit 2012 will also release an exclusive booklet on Brand India Pharma by India Brand Equity Foundation ( IBEF) & Pharmexcil. A detailed & exclusive Whitepaper on “The Future of Clinical Trial Services (Phase I to IV) in India – The Road Ahead” prepared by Ms Nidhi Saxena, Founder, President & CEO,. Karmic Lifesciences will also be released.

The Summit will witness more than top 20  Asia Pharmaleaders debating on the complex issues on how the indian healthcare industry is charting out its map in the global landscape. Those who will debate & Address at the Summit are powerful faces & voices of the Indian Pharmaceutical & Biotech Industry such as Dr Mahesh Burande, Hon Director, Institute of Pharmaceutical Education and Research (IPER) on Challenges and Opportunities for Indian Pharma Industry to become Pharma Superpower in 2020, Mr. Kewal Handa, Ex Managing Director, Pfizer Ltd. & Wyeth Ltd on Branded Formulations VS Branded Generics, 2012 Pharmaceutical Diversification Trends, Making of Dr Batras Brand . Indian Experience VS Global Challenges by Dr Mukesh Batra.Founder Chairman, Dr Batra’s Positive Clinic, Are We Ready For A Mechanical Artificial Heart for Indian Patients by Dr Mukesh Hariawala, Renowned Cardiac Surgeon & Healthcare Economist, Harvard Medical School Affiliated Hospitals, Boston, USA, Regulatory Challenges of Indian Pharmaceutical companies. A CEO’s Perspective by Dr. Shenaz Khaleeli Co- Founder & Technical Director, PharmaLeaf India Pvt Ltd, Delivering value in the Supply Chain by Ms Sue Arden, VP Life Sciences & Healthcare.  DP DHL, Singapore, Neutraceutical & OTC Sector,the European Market Challenge by François Licoppe, CEO,Eubage Laboratory, Belgium, Indian Pharma Industry ,Challenges & Key Issues in partnership, Alliances & Co-Marketing by Shivkumar Kunchithapatham, Managing Director,  Eisai Pharmaceuticals India Private Limited, Innovative Trends in Facial Aesthetics – Indian Challenges with Global Experiments by Dr. Shuba Dharmana, Cosmetic Dermatologist, Laser Specialist, Hair Transplant Surgeon by CEO Dr.Shuba Skin & Laser Clinic . Besides Dr Rajaram Samant, Founder Chairman, Akumentis Healthcare Ltd, S.V.Veerramani, CMD, Fourrts(India) Laboratories Pvt Ltd, Dr. B.R. Shetty, Founder,Managing Director & CEO, NMC Healthcare, Abu Dhabi, U.A.E, Dr Rashmi Shetty, Cosmetologist, and pioneer and leading expert for Non-Surgical Aesthetic Medicine,Dr Kannan Vishwanath, VC, MD, Aanjaneya Lifecare Ltd will be debating on a high powered panel discussion Brand India Pharma.

Maharashtra Governor Kateekal Sankaranarayanan  will give away the much awaited Pharmaleaders Business Leadership Awards 2012 in as many as 33 categories where presently Nominations are underway & votings for the Nominations to choose the Winner is going on in  more than 9 countries with a sample size of 5 Lakh 56 thousand & 674 voters spread across 21  states & 4 industry verticals in India via online, sms & physical interviews . Commenting on the Award Nominations, Jury Chairman Satya Brahma said “Past Award winners from this platform  have shown how companies can help boost sustainable growth and development, they can be a tremendous source of innovative and sustainable solutions, which help transform people’s lives for the better & these Awards will highlight the critical role of the private sector in stimulating sustainable economic growth and development. A detailed Analysis of career graph/History or notable achievement is looked at to get the final four names. Factors such as ,   Financial management, Decision making roles and business impact, Business ethics, Managing rapid growth,Innovation,adapting to change, Strategic partnerships, Leadership roles, Marketing strategies, Corporate philanthropy/contributions to society will be the key to win the prestigious Award Title in various categories.

The 5^th Annual Pharmaceutical Leadership Awards will be presented in a star-studded gala award evening on 21^st September in Mumbai & the Winners will be announced in the Evening at the Award Night.

Celebrity Doctors: After Cinema & Sports, Brand Ambassadors May Well Come Medical Veterans

Celebrity Doctors: After Cinema & Sports, Brand Ambassadors May Well Come Medical Veterans

Pharmaleaders Research reveal the rising interest of the Healthcare Sector’s aggressive campaign to rope Celebrity Doctors. Dr Mukesh Hariawala, Dr Shuba Dharmana, Dr Devi Shetty, Dr Naresh Trehan top the List.

Maharashtra, Mumbai, Friday 7^th September 2012 : In the run up to the 5^th Annual Pharmaceutical Leadership Summit & Business Leadership Awards 2012 ( www.asiapharmaleaders.com ) organized by Pharmaleaders Group ( www.pharmaleaders.co.in ) in association with Pharmexcil, BSE India, IBEF & host of other trade bodies & pressure group in healthcare sector with the support of Ministry of Commerce & Industries in the commercial capital of India on 21^st September 2012 at Hotel Hilton, Mumbai, India, the  research & survey conducted by Breakfastnews TV (www.breakfastnew.tv )& Pharmaleaders Magazine bring out some startling results. We all know that in a country like India where Brand Loyalty largely stem from endorsements from Brand Icons largely from Bollywood, Sport stars mostly from Cricketing world. With the marketing becoming tougher & competative, many healthcare companies are revisiting their marketing plans & strategies in order to have a grip in the market. Indian Healthcare Market is largely dominated by endorsements from the doctors by the Medical Representatives in updating them on the benefits of the products. However, in OTC market, the scenario is different & huge money is spent on print & Electronic Advertisements & the big fish here are matinee idols & Sport stars.

India is a country where people love to live in dreams. They worship celebrities & build temples for them without knowing their real background. Celebrities may be cricket stars like Sachin Tendulkar, Mahindra Singh Dhoni or film stars like Amitabh Bachchan, Salman Khan, and Shah Rukh Khan etc. They are treated as God. Marketers use this very proposition so as to influence their target customers, maybe existing or potential ones. For this they rope in these celebrities and give them whopping amount of money. But the bigger issue is says Satya Brahma, Editor-In-Chief of Pharmaleaders “Is it good for pharmaceutical companies to pay celebrities to be spokespeople to raise awareness of medical conditions?, also Given the power of of celebrities to influence people, pharmaceutical companies have come out with a innovative & cost effective plans, that of roping Celebrity Doctors & Medical Wizards”. The Indian OTC pharmaceuticals market generated total revenues of $1.8 billion in 2010, representing a compound annual growth rate (CAGR) of 6.4% for the period spanning 2006-2010. -Vitamins and minerals sales proved the most lucrative for the Indian OTC pharmaceuticals market in 2010, generating total revenues of $471.2 million, equivalent to 25.8% of the market's overall value. -The performance of the market is forecast to decelerate, with an anticipated CAGR of 4.6% for the five-year period 2010-2015, which is expected to lead the market to a value of $2.3 billion by the end of 2015 said Satya.

The Indian pharmaceutical sector has come a long way, from being a small player in 1970, to becoming a prominent provider of healthcare products, meeting almost 95 per cent of the country‘s pharmaceutical needs today. Pharmaleaders Research reveals that the pharmaceutical industry in India has a unique and exciting opportunity to grow & prosper. India accounts for 8 % of global pharmaceutical production. It is the third largest in terms of volume and fourteenth in terms of value. Indian firms produce about 60000 generic brands across 60 therapeutic categories and 500 active pharmaceutical ingredients (APIs) approximately. India boasts an export of generic drugs worth US $11 billion and the generic drug market is predicted to grow at a CAGR of 17 per cent between 2010-11 and 2012-13.2 $5.5 bn in 2000 to US $ 25 bn in 2020.

Indian Pharma Majors such as Ranbaxy, Paras Pharma, Elder Pharmaceuticals, Mankind, Alkem labs, Nicholas Piramal, Abbott, Pfizer, GSK etc spend a huge money on Celebrity Branding. Ranbaxy reportedly paid huge amount for its star Brands Voilini & Revital to stars such as Salman Khan, Yuvraj Singh, Tisca Chopra & lately Sonali Bendre. Sources close to Pharmaleaders reveal that the endorsements give huge returns given Indian typical mindset & lack of wider knowledge. However lately, Pharma Companies balance sheet reflected more money to Celebrity Fees than sometimes a unit’s manufacturing cost.

To combat these challenges, Pharmaceutical & Medical Companies have started out looking at leading faces & credible voices in the medical practice whose knowledge on the product & endorsement appeal has a bigger impact than the Superstars said an Ad Agency roped in for finding star Doctors after giving a try in Sports & Cinema. “Given the uncertainty of Star Appeal when they run in controversies or out of form players result in negative results & moreover they have bigger problems, egos & status” said Tanya who heads a Mumbai based Ad Agency. She admitted that next ibn line will be the Doctors who will have the mass appeal & their fees will be lesser compared to bigger fees by the Stars. It is no surprising that more & more Pharma Companies are getting into OTC segment to reach out to masses & pocket a bigger share”.

With these objectives, to know the pulse of consumers, Pharmaleaders undertook a research to find out the reasons why Doctors are increasingly becoming the favorite for the Drug & FMCG Companies. How about celebrities being paid to promote specific OTC treatments? Is that OK? Do such celebrity spokespeople provide a good return on investment for pharmaceutical marketers?. These are the questions that come to mind. So this prompted Pharmaleaders Researchers to know the pulse of people.

Pharma leaders sample profiles included the demographic characteristics of the respondent consumers covered in the analysis. Demographic factors like age, education, occupation, income, family size have a direct influence on the product/ brand choice. To ascertain the views of both male and female consumers, almost equal numbers of respondents are selected for the study. On the basis of age, the respondents are classified into five categories viz. below 20 years, 21-30 years, 31-40 years, 41-50 years, and above 50 years. Around 39 percent respondents are in the age group of 21-30 years. Another 27 percent are in the age group of 31-40 years. Around 16 percent are in the age group of 41-50 years, followed by above 50 years (13 percent), and below 20 years (5 percent). It is observed that majority of respondents comprising 73 percent are either graduates or post graduates. The remaining 27 percent have below graduation educational background. It is also observed that private employees comprise 38 percent of sample followed by housewives (25 percent), and government employees (18 percent). The remaining are students, businessmen and professionals. It is found that 43 percent respondents are in the middle income group (Rs. 10,001 to 20,000/pm). At the same time, 31 percent belong to low income group (Below Rs. 10,000/ pm). The remaining 26 percent belong to high income category (above Rs. 20,000/pm). It is seen that around 63 percent respondents have 3-4 members in their families. Around 26 percent have more than 4 three members. Another 11 percent have two or less members. It is observed that 62 percent respondents spend below Rs 300/per month on a vitamin product. The remaining 38 percent respondents spend above Rs 200/- per month. This gives occupation wise, income wise, and lifecycle wise distribution of sample consumers of Pharmaceutical Over The Counter Products (OTC). The behavior of urban respondents towards OTC products in terms of influencing factors such as buying habits, and brand loyalty are also analyzed.

The Respondents who were asked to answer, given the choice, whom will they look at their choice to influence their buying habits, the list were endless with big medical names such as Dr Ramakant Panda, Dr Bhattacharya, Dr Sidharth Shah, Dr N.S.Laud etc. But close to the maximum choices who will have mass appeal & who topped the research are celebrity Indo-American Heart Surgeon Dr Mukesh Hariawala, Eminent cardiologists Dr Naresh Trehan & Devi Shetty. Dr Shuba Dharmana who is a Dermatologist appeared favorite for endorsing skin & wellness products. But the big question is will these Doctors risk attaching their names to a specific company or a Brand, that time can answer.

India Needs Doctors, Nurses, Health Insurance, PHU’s & Quality free Medicines- - Pharmaleaders-

India Needs Doctors, Nurses, Health Insurance, PHU’s & Quality free Medicines- - Pharmaleaders-

Industry Veterans Dr Mukesh Batra, Mr. Kewal Handa, Dr B.R Shetty, Dr Mukesh Hariawala,Dr Kannan Vishwanath, Shivkumar Kunchithapatham, Dr Rajaram Samant, Dr Rashmi Shetty, Dr Shuba Dharmana, François Licoppe, V.Veerramani, Dr Mahesh Burande to address

Maharashtra, Mumbai, 2^nd September 2012: India needs doctors, nurses and health insurance, Public Healthcare Units, Free Medicines for poor &  & moreover the brand India Pharma Image cant be realized unless & until a strong healthcare policy is in place & healthcare reforms to address the challenges of getting quality medicines at affordable price, feel the illustrious list of speakers who will gather to debate at historic & prestigious 5^th Annual Pharmaceutical Leadership Summit & Business Leadership Awards 2012 ( www.asiapharmaleaders.com )( www.breakfastnews.tv ). Pharmaleaders, a Mumbai based healthcare media group (www.pharmaleaders.co.in ) in association with country’s biggest trade bodies & associations is debating the critical issues on 21^st September 2012 on a Theme “Brand India Pharma, Beyond Generics. Leading with Resilience: Coming Back from Challenge and Heading Towards Super-power Status”.

Ø  India has just seven doctors per 10,000 people, while China has 14 per 10,000

Ø  Less than 23 percent of Indians are covered by policies

Ø  95 percent of the population in China are  covered by some sort of insurance, India is nil

Ø  There are just Eleven  hospital beds per 10,000 people in India, compared with 41 per 10,000 in China.

Ø  Access to basic Medicine by the large chunk of Indian Population is still an issue.

Ø  Quality Medicines at Affordable Prices is still a slogan.

The Leadership Summit will witness the who’s & Who’s of Indian Healthcare Industry with 10 plenary sessions to cover the burning issues of the sector such as Challenges and Opportunities for Indian Pharma Industry to become Pharma Superpower in 2020 by  Dr Mahesh Burande, Hon Director,Institute of  Pharmaceutical Education and Research (IPER). Branded Formulations VS Branded Generics, 2012 Pharmaceutical Diversification Trends by  Kewal Handa, Ex Managing Director, Pfizer Ltd. & Wyeth Ltd, Making of Dr Batras Brand,  Indian Experience VS Global Challenges by Dr Mukesh Batra.Founder Chairman, Dr Batra’s Positive Clinic, Are We Ready For A “Mechanical Artificial Heart For Indian Patients by Dr Mukesh Hariawala, Cardiac Surgeon & Healthcare Economist, Harvard Medical School Affiliated Hospitals, Boston, USA. Regulatory Challenges of Indian Pharmaceutical companies. A CEO’s Perspective by Dr. Shenaz Khaleeli ,Co- Founder & Technical Director, PharmaLeaf India Pvt Ltd, Delivering value in the Supply Chain by Sue Arden, VP Life Sciences & Healthcare.  DP DHL, Singapore, Neutraceutical & OTC Sector: The European Market Challenge by François Licoppe, CEO,Eubage Laboratory, Belgium, Indian Pharma Industry : Challenges & Key Issues in partnership, Alliances & Co-Marketing by  Shivkumar Kunchithapatham, Managing Director,  Eisai Pharmaceuticals India Private Limited, Innovative Trends in Facial Aesthetics – Indian Challenges with Global Experiments by Dr. Shuba Dharmana Cosmetic Dermatologist, Laser Specialist, Hair Transplant Surgeon, CEO Dr.Shuba Skin & Laser Clinic. The Event will see a high powered panel discussion on Globalization of Indian Brands: Key Challenges & Opportunities by the Experts such as Mr. Kersi Tavadia, CIO, Bombay Stock Exchange Limited,.            Mr.Rakesh Bhargava, Chairman, Fresenius Kabi Oncology Ltd, Dr Shuba Dharmana, Dermatologist, Hair Transplant surgeon & Aesthetic & Laser, Dr Mahesh Burande, Hon.Director Institute of Pharmaceutical Education and Research & Consultant, Dr Rajaram Samant, Founder Chairman, Akumentis Healthcare Ltd, Mr S.V.Veerramani, CMD, Fourrts(India) Laboratories Pvt Ltd, Dr. B.R. Shetty, Founder,Managing Director & CEO, NMC Healthcare, Abu Dhabi, U.A.E, Dr Mukesh Batra, Chairman, Dr Batra's Positive Health,     Dr Rashmi Shetty, Cosmetologist, and pioneer and leading expert for Non-Surgical Aesthetic Medicine,  Dr Kannan Vishwanath, VC, MD, Aanjaneya Lifecare Ltd.

Speaking on the high panel speaker & battery of experts who will gather to speak at Pharmaleaders Annual Meet, Satya Brahma, Editor-In-Chief of Breakfast news ( www.breakfastnews.tv ( & Pharmaleaders said “Unlike Europe such as Canada & others, Healthcare is given a top priority & the reforms are on top of the Agenda & the respective Governments are concerned about it, In India Healthcare is  not delivered through a publicly funded health care system & lacks transparency & synergy of systems, poor policies arising out of a fractured mandate, Coalition  government at the Center are paralyzing Indian healthcare sector”. This Conglometer will address the core Issues added satya Brahma.

The Indian Pharma industry accounts for ~20% (volume terms) of the global generics industry. During the 11th plan period, the domestic pharma market grew at 14% CAGR and exports grew at 19% CAGR with anti infective, anti asthmatic and anti hypertensive being the major therapeutic categories. USA, Russia, Germany, Austria and UK are the top export destinations with USA alone accounting for almost 20% of total exports. Although the industry is fragmented, the large and medium sized pharma companies contribute to ~75% of the domestic sales and over 90% of exports. 

The overall pharmaceutical industry was pegged at Rs 1,000 billion (~USD 20 billion) with the domestic pharma industry at over Rs 600 billion (~USD 12 billion) in 2009-10. The bulk drugs contributed to about Rs 420 billion (USD 8.4 billion). The country has about 10,563 manufacturing units with about 300 large and medium units and remaining in the small scale and unorganized sector.   The Department of Pharma in its 12th plan aims to increase the size of the industry to USD 60 billion with exports contributing to over USD 25 billion. The contribution of bulk drugs is aimed at USD 28 billion (47% contribution). About USD 300 billion worth of patented drugs are expected to become generic by 2015 and this would a major driving factor for our exports. The Leadership Event will felicitate the shining stars of Indian Healthcare sector at 5^th Annual Pharmaceutical Leadership Awards 2012.